做多
已更新

CWBR cheap anti-aging stock

CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.

CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.

Cantor Fitzgerald brokerage has a $2.5 price target for it.
交易开始
CWBR Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。